OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Skoulidis on the Implications of the POSEIDON Trial of Tremelimumab Plus Durvalumab in NSCLC

April 18th 2023

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the clinical implications for data from the combination of tremelimumab plus durvalumab and chemotherapy in metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

Dr Desai on the Efficacy of Divarasib Plus Cetuximab in KRAS G12C–Mutant CRC

April 18th 2023

Jayesh Desai, MBBS, FRACP, discusses efficacy data for the combination of divarasib plus cetuximab in patients with colorectal cancer harboring a KRAS G12C mutation from a phase 1B study.

Dr Bryant on Utilizing Nivolumab With SOC in Grade Group 5 Prostate Cancer

April 18th 2023

John Michael "JM" Bryant, MD, discusses the combination of nivolumab with standard of care in the management of patients with prostate cancer, detailing the results of the interim analysis of the phase 2 trial.

Dr Mohammed on the Challenges of Diagnosing BPDCN

April 18th 2023

Turab J. Mohammed, MD, discusses challenges associated with the diagnosis of blastic plasmacytoid dendritic cell neoplasm, and strategies to improve early diagnosis of this disease.

Dr Eisfeld on Updated Guidelines for the Classification of AML

April 18th 2023

Ann-Kathrin Eisfeld, MD, discusses recent changes to the classification of acute myeloid leukemia, and potential challenges accompanying these new guidelines.

Dr Suvannasankha on the Safety/Efficacy of REGN5459 in R/R Multiple Myeloma

April 18th 2023

Attaya Suvannasankha, MD, discusses the safety and efficacy of REGN5459, a BCMAxCD3 bispecific antibody with low affinity to CD3 on T cells, in relapsed/refractory multiple myeloma.

Dr Sabari on Preliminary Data From a Phase 1 Study of LY3537982 in KRAS G12C–mutant Advanced Solid Tumors

April 17th 2023

Joshua K. Sabari, MD, discusses key findings from the phase 1 LOXO-RAS-20001 study of the KRAS G12C inhibitor LY3537982 in KRAS G12C–mutant advanced solid tumors.

Dr Srour on the Phase 1 TRAVERSE Study of ALLO-316 in Metastatic Clear Cell RCC

April 17th 2023

Samer A. Srour, MB, ChB, MS, discusses the study design of the phase 1 TRAVERSE study, and key data on the use of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.

Dr Horwitz on the FDA Approval of Omidubicel in Blood Cancers Requiring Transplant

April 17th 2023

Mitchell E. Horwitz, MD, discusses the significance of omidubicel as an FDA-approved treatment option to reduce the risk of infection in patients with blood cancers and highlights key findings from the pivotal phase 3 trial.

Dr Heymach on Results from the AEGEAN Trial of Durvalumab in Resectable NSCLC

April 16th 2023

John V. Heymach, MD, PhD, discusses findings the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Dr Islam on Treatment of Patients With Hodgkin Lymphoma With or Without HIV

April 16th 2023

Jessica Yasmine Islam, PhD, MPH, discusses the treatment of patients with Hodgkin’s lymphoma who do or do not have HIV.

Women in Oncology: The Evolution of Active Mentorship

April 14th 2023

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the differences that can arise between the mentorship strategies of men and women and the importance of finding mentors that help with individual career growth and personal goal accomplishment.

Women in Oncology: Early Career Growth and Institutional Change

April 14th 2023

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss their early career experiences as women in the oncology field.

Dr Ademuyiwa on the Implications of the KEYNOTE-522 Trial in Early-Stage TNBC

April 14th 2023

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the implications of the phase 3 KEYNOTE-522 trial in high-risk, early-stage triple-negative breast cancer.

Dr Liu on the Activity of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

April 14th 2023

Stephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.

Dr McGregor on Next Steps For Cabozantinib Plus Atezolizumab in Advanced RCC

April 14th 2023

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AML

April 14th 2023

Bradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.

Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in Melanoma

April 14th 2023

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

Dr Fader on Letrozole With or Without Paclitaxel and Carboplatin in Ovarian Serous Carcinoma

April 13th 2023

Amanda Nickles Fader, MD, discusses the randomized, phase 3 NRG-GY019 trial evaluating letrozole with or without paclitaxel and carboplatin in patients with stage II to IV primary low-grade serous carcinoma of the ovary or peritoneum.

Dr Slomovitz on the Classification of Molecular Subtypes to Guide Treatment in Endometrial Cancer

April 13th 2023

Brian M. Slomovitz, MD, discusses the classification of molecular subtypes to guide treatment and care in endometrial cancers.